Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H22O9 |
Molecular Weight | 394.3726 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C2=C3OC(CC(C)=O)=CC(=O)C3=C(C)C=C2O
InChI
InChIKey=HKIKAXXIWJHWLY-ZIIYPAMZSA-N
InChI=1S/C19H22O9/c1-7-3-10(22)14(19-17(26)16(25)15(24)12(6-20)28-19)18-13(7)11(23)5-9(27-18)4-8(2)21/h3,5,12,15-17,19-20,22,24-26H,4,6H2,1-2H3/t12-,15-,16+,17-,19+/m1/s1
Aloesin is a chromone derivative isolated from aloe vera. It has many biological effects, such as wound and burn healing properties, and antioxidant, free radical scavenging, anti-inflammatory, and immunomodulatory effects. Aloesin has been shown to be a potent and selective inhibitor of tyrosinase. It exhibited direct inhibitory effects on melanogenesis. Aloesin treatment showed pigmentation suppression in a dose-dependent manner. Thus, aloesin may be used as an agent that inhibits melanin formation induced by UV radiation. Aloesin is thought to be one of the active ingredients in regards to the anti-diabetic activity of Aloe. Aloesin exerts its anticancer effect through the MAPK signaling pathway. It is a novel therapeutic drug for ovarian cancer treatment.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10403123 |
0.1 mM [IC50] | ||
Target ID: map04010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28702312 |
|||
Target ID: GO:0060395 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28478809 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin derivatives in Aloe vera. | 2002 Nov |
|
Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. | 2002 Oct |
|
Aloesin inhibits hyperpigmentation induced by UV radiation. | 2002 Sep |
|
Aloesin as a medical food ingredient for systemic oxidative stress of diabetes. | 2015 Aug 10 |
|
Aloesin Suppresses Cell Growth and Metastasis in Ovarian Cancer SKOV3 Cells through the Inhibition of the MAPK Signaling Pathway. | 2017 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12372097
100 mg ⁄ g vehicle, four times daily for 15 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21821088
Aloesin did not induce reverse mutations in Salmonella typhimurium and Escherichia coli at any of the tested dose levels up to 10,000 ug/plate. Similarly, aloesin did not increase the incidence of chromosome aberrations when incubated with Chinese hamster lung cells at any of the tested concentrations up to 10,000 ug/mL.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1571
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
160190
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | |||
|
C069868
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | |||
|
30861-27-9
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | |||
|
DTXSID80184877
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | |||
|
Y27M69Y8ES
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY | |||
|
631262
Created by
admin on Fri Dec 15 17:29:42 GMT 2023 , Edited by admin on Fri Dec 15 17:29:42 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD